Behringwerke Aktiengesellschaft

Hoechst Aktiengesellschaft

Hans Bohn

Wilhelm Winckler

Ernst Weinmann

Ferdinand Stutzinger

Walter Kraus

Heinz Haupt

Fritz Emmerich

A protein PP.sub.18 is isolated having the following characteristics:

Isolated tissue protein PP.sub.18

Tissue protein PP.sub.19, a process for obtaining it, and its use

The protein PP.sub.21 which has the following characteristics:

Tissue protein PP.sub.21, a process for obtaining it and its use

The protein PP.sub.20 is described, this having the following characteristics:

Protein PP.sub.20, a process for obtaining it, and its use

Membrane-associated proteins, called MP.sub.2, and a process for obtaining them are described. The proteins have the following parameters:

Membrane-associated proteins (MP.sub.2), a process for obtaining them,

Tissue protein PP.sub.4, a process for isolating it and its use

Protein PP.sub.13 is isolated from human placental tissues using a variety of methods, e.g., immunoadsorption. The protein has utility in production of an antiserum which has diagnostic applications. The placental specific proteins (e.g., PP.sub.13) are frequently detected in increasing amounts in women as pregnancy advances, and in patients with tumors especially of the tryphoblastic and embryonal types.

New protein PP.sub.13 extracted from human placental tissues and use

The protein PP.sub.17, which has (a) an electrophoretic mobility in the range between .beta..sub.1 - and .alpha..sub.2 -globulins, (b) an isoelectric point of 5.25.+-.0.20, (c) a sedimentation coefficient S.sub.20.sup.o, w of 2.7.+-.0.1 S, (d) a molecular weight, determined in polyacrylamide gel containing sodium dodecyl sulfate (SDS), of 38,000.+-.2,000, (e) an extinction coefficient E.sub.1cm.sup.1% (280 nm) of 8.5.+-.0.4 and (f) a carbohydrate content of 2.1.+-.0.9% containing 0.3.+-.0.2% of mannose, 0.4.+-.0.2% of galactose, 0.2.+-.0.1% of xylose, 1.0.+-.0.3% of N-acetyl-glucosamine and 0.2.+-.0.1% of N-acetyl-neuramin acid, is described. A process for concentrating and isolating it and its use are also described.

Protein (PP.sub.17), a process for concentrating and isolating it and

What are disclosed are an isolated tissue protein, denominated PP16, which can be used to prepare anti-sera useful as diagnostic agents, said protein being found in extracts of some human organs such as the placenta, spleen, stomach, and lung and being capable of isolation therefrom and which has the following properties:

Protein and process for isolating it

What are disclosed are a protein, PP.sub.9, useful for the diagnosis and monitoring of diseases involving tissue degradation, and a method for its isolation, said protein having:

Protein PP.sub.9, process for its enrichment and its isolation and its

What are disclosed are a protein, PP.sub.15, useful for preparing antisera and as an immunosuppressive agent, and a method for isolating the pure protein from human placentas.

New protein PP.sub.15, a process for its preparation and its use

What are disclosed are a new protein, PP.sub.11, obtainable from placental tissue, methods for isolating the protein in concentrated form, methods for making an antiserum to said protein, and methods for using said antiserum for monitoring pregnancy and for detecting and monitoring tumors and/or their therapy.

Protein, PP.sub.11, a process for its preparation and its use

A new placenta-specific protein (PP.sub.10) and a process for isolating it are described.

Placenta-specific tissue protein PP.sub.10

A new soluble tissue protein (PP.sub.8) and a process for isolating it from human organs is described. The protein has antigenic properties. In the case of diseases which involve tissue disintegration its presence in the blood in increased concentration can be established.

Ubiquitary tissue protein PP.sub.8

What are disclosed are methods for the prevention of pregnancy, or the interruption of pregnancy, in primates by the parenteral administration of a substance which immunologically reacts with the protein PP.sub.5 or induces immunologically reactive substances directed against PP.sub.5 and pharmaceutical preparations containing such a substance.

Growing community of inventors

Marburg, Germany

Hans Bohn